Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

13.00 +0.31 (+2.44%)
Streaming Delayed Price Updated: 2:00 PM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025
These stocks to buy are expected to double by 2025 and could turn mundane market returns into something bigger with a willingness to bet. 
Via InvestorPlace
NovoCure (NVCR) Q1 2024 Earnings Call Transcript
NVCR earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Unveiling 8 Analyst Insights On NovoCure
 
Via Benzinga
NVCR Stock Earnings: NovoCure Beats EPS, Beats Revenue for Q1 2024
NVCR stock results show that NovoCure beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
From Novocure
Via Business Wire
Why NovoCure Stock Soared 18.3% This Week
Novocure announced encouraging results in a phase 3 trial for its TTFields therapy. 
Via The Motley Fool
Why Novocure Stock Is Jumping Today
Novocure had good news mixed with some not-so-good news. 
Via The Motley Fool
Peeling Back The Layers: Exploring NovoCure Through Analyst Insights
 
Via Benzinga
Novocure Reports First Quarter 2024 Financial Results
From Novocure
Via Business Wire
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
From Novocure
Via Business Wire
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
From Novocure
Via Business Wire
NovoCure Ltd. (NASDAQ: NVCR) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Novocure to Report First Quarter 2024 Financial Results
From Novocure
Via Business Wire
Novocure Stock Soars, Its Lung Cancer Electric Field Treatment Slows Progression To Brain, Data Shows
Novocure's Phase 3 METIS trial results: TTFields therapy, combined with supportive care, significantly prolongs time to intracranial progression for NSCLC brain metastases patients compared to... 
Via Benzinga
Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday. 
Via Benzinga
Topics Stocks
Novocure Surges And Flashes A Bullish Sign On Promising Results For Brain Cancer Treatment
The company uses electrical fields to interrupt the rampant cellular division characteristic of cancer. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
From Novocure
Via Business Wire
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
Via Benzinga
NovoCure (NVCR) Q4 2023 Earnings Call Transcript
NVCR earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
From Novocure
Via Business Wire
Earnings Scheduled For February 22, 2024
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million. 
Via Benzinga
AI Drives Tech Rebound, Oil Soars, Bitcoin Tumbles: What's Driving Markets Thursday?
During midday Thursday trading in New York, U.S. stocks displayed mixed performance, with the technology sector outperforming others as investors maintained a bullish outlook on artificial... 
Via Benzinga
Topics Artificial Intelligence
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Why Is Cancer Focused Novocure Stock Trading Higher Today?
Novocure's TTFields therapy gains FDA acceptance for non-small cell lung cancer treatment after platinum-based therapy. PMA filing under FDA review. Decision expected in 2H 2024. 
Via Benzinga
Fastenal Posts Upbeat Earnings, Joins NovoCure, Taiwan Semiconductor Manufacturing And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mixed, with the Dow Jones index falling around 50 points on Thursday. Shares of Fastenal Company (NASDAQ: FAST) rose during Thursday’s session after the company reported... 
Via Benzinga
Topics Stocks
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of WD-40 Company (NASDAQ: WDFC) rose sharply during Wednesday’s session after the company reported better-than-expected first-quarter results. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.